advertisement
Abstract #20821 Published in IGR 10-1
Physician attitudes regarding prostaglandin treatment for glaucoma in the United States and Europe
Stewart WC; Stewart JA; Nelson LA; Kruft BEuropean Journal of Ophthalmology 2008; 18: 199-204
PURPOSE. To evaluate physician use of prostaglandins (latanoprost, travoprost, and bimatoprost) in the United States (US) and Europe (EU). METHODS. One thousand multiple-choice surveys were distributed via e-mail in the US and EU. RESULTS. The authors received 71 responses (US 40 [8%] and EU 31 [6%]). Physicians preferred prostaglandin monotherapy (US 39 [98%] and EU 22 [71%], p=0.003), usually latanoprost (US 32 [80%] and EU 22 [71%], p=0.45). When more efficacy was required, US physicians would typically switch (23 [58%]) and EU physicians would add therapy (22 [71%], p=0.007). In both continents 45% of respondents stated bimatoprost was more efficacious. CONCLUSIONS. US and EU physicians prefer prostaglandin monotherapy, most commonly latanoprost. Bimatoprost is often perceived as more effective, but having a higher incidence of conjunctival hyperemia.
Dr. W.C. Stewart, Carolina Eye Institute, University of South Carolina, School of Medicine, Columbia and PRN Pharmaceutical Research Network, LLC, Dallas, USA
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)